A Study of CDX-622 in Participants With Mild to Moderate Asthma
← catalyst calendarNCT07330778 · readout ≤ 224 d
Sponsored by Celldex Therapeutics (industry) · CLDX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-01 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mild to Moderate Asthma
Intervention
- Drug: CDX-622
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma.
measured Day 1 up to Day 85 (12 weeks)
Permalink · CLDX's whole pipeline · Catalyst calendar · Every registered study · What changed